186 related articles for article (PubMed ID: 34406312)
1. Low molecular weight heparin is useful in adult COVID-19 inpatients. Experience during the first Spanish wave: observational study.
Gonzalez-Porras JR; Belhassen-Garcia M; Lopez-Bernus A; Vaquero-Roncero LM; Rodriguez B; Carbonell C; Azibeiro R; Hernandez-Sanchez A; Martin-Gonzalez JI; Manrique JM; Alonso-Claudio G; Alvarez-Navia F; Madruga-Martin JI; Macias-Casanova RP; García-Criado J; Lozano F; Moyano JC; Sanchez-Hernandez MV; Sagredo-Meneses V; Borras R; Bastida JM; Hernández-Pérez G; Chamorro AJ; Marcos M; Martin-Oterino JA
Sao Paulo Med J; 2022; 140(1):123-133. PubMed ID: 34406312
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial.
Spyropoulos AC; Goldin M; Giannis D; Diab W; Wang J; Khanijo S; Mignatti A; Gianos E; Cohen M; Sharifova G; Lund JM; Tafur A; Lewis PA; Cohoon KP; Rahman H; Sison CP; Lesser ML; Ochani K; Agrawal N; Hsia J; Anderson VE; Bonaca M; Halperin JL; Weitz JI;
JAMA Intern Med; 2021 Dec; 181(12):1612-1620. PubMed ID: 34617959
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic dosing of low-molecular-weight heparin may decrease mortality in patients with severe COVID-19 infection.
Canoglu K; Saylan B
Ann Saudi Med; 2020; 40(6):462-468. PubMed ID: 33307734
[TBL] [Abstract][Full Text] [Related]
4. Compression stockings in addition to low-molecular-weight heparin to prevent venous thromboembolism in surgical inpatients requiring pharmacoprophylaxis: the GAPS non-inferiority RCT.
Shalhoub J; Lawton R; Hudson J; Baker C; Bradbury A; Dhillon K; Everington T; Gohel MS; Hamady Z; Hunt BJ; Stansby G; Warwick D; Norrie J; Davies AH
Health Technol Assess; 2020 Dec; 24(69):1-80. PubMed ID: 33275096
[TBL] [Abstract][Full Text] [Related]
5. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery.
Felder S; Rasmussen MS; King R; Sklow B; Kwaan M; Madoff R; Jensen C
Cochrane Database Syst Rev; 2019 Aug; 8(8):CD004318. PubMed ID: 31449321
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic anticoagulants for people hospitalised with COVID-19.
Flumignan RL; Tinôco JDS; Pascoal PI; Areias LL; Cossi MS; Fernandes MI; Costa IK; Souza L; Matar CF; Tendal B; Trevisani VF; Atallah ÁN; Nakano LC
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD013739. PubMed ID: 33502773
[TBL] [Abstract][Full Text] [Related]
7. Low-molecular-weight heparin use in coronavirus disease 2019 is associated with curtailed viral persistence: a retrospective multicentre observational study.
Pereyra D; Heber S; Schrottmaier WC; Santol J; Pirabe A; Schmuckenschlager A; Kammerer K; Ammon D; Sorz T; Fritsch F; Hayden H; Pawelka E; Krüger P; Rumpf B; Traugott MT; Glaser P; Firbas C; Schörgenhofer C; Seitz T; Karolyi M; Pabinger I; Brostjan C; Starlinger P; Weiss G; Bellmann-Weiler R; Salzer HJF; Jilma B; Zoufaly A; Assinger A
Cardiovasc Res; 2021 Dec; 117(14):2807-2820. PubMed ID: 34609480
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of venous thromboembolism prophylaxis with fondaparinux or low molecular weight heparin in a large cohort of consecutive patients undergoing major orthopaedic surgery - findings from the ORTHO-TEP registry.
Donath L; Lützner J; Werth S; Kuhlisch E; Hartmann A; Günther KP; Weiss N; Beyer-Westendorf J
Br J Clin Pharmacol; 2012 Dec; 74(6):947-58. PubMed ID: 22515679
[TBL] [Abstract][Full Text] [Related]
9. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Di Nisio M; Porreca E; Candeloro M; De Tursi M; Russi I; Rutjes AW
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD008500. PubMed ID: 27906452
[TBL] [Abstract][Full Text] [Related]
10. Impact of proactive low-molecular weight heparin therapy on outcomes in COVID-1.
Gormez S; Gumusel HK; Ekicibasi E; Degirmencioglu A; Paudel A; Akan G; Atalar F; Erdim R; Eroglu E; Dagdelen S; Sariguzel N; Kirisoglu CE; Pamukcu B
Bratisl Lek Listy; 2021; 122(8):582-589. PubMed ID: 34282625
[TBL] [Abstract][Full Text] [Related]
11. Use of low-molecular weight heparin, transfusion and mortality in COVID-19 patients not requiring ventilation.
Grandone E; Tiscia G; Pesavento R; De Laurenzo A; Ceccato D; Sartori MT; Mirabella L; Cinnella G; Mastroianno M; Dalfino L; Colaizzo D; Vettor R; Intrieri M; Ostuni A; Margaglione M;
J Thromb Thrombolysis; 2021 Oct; 52(3):772-778. PubMed ID: 33844150
[TBL] [Abstract][Full Text] [Related]
12. The Association of Low Molecular Weight Heparin Use and In-hospital Mortality Among Patients Hospitalized with COVID-19.
Shen L; Qiu L; Liu D; Wang L; Huang H; Ge H; Xiao Y; Liu Y; Jin J; Liu X; Wang DW; Peterson ED; He B; Zhou N
Cardiovasc Drugs Ther; 2022 Feb; 36(1):113-120. PubMed ID: 33394360
[TBL] [Abstract][Full Text] [Related]
13. Low molecular weight heparin for prevention of central venous catheter-related thrombosis in children.
Pelland-Marcotte MC; Amiri N; Avila ML; Brandão LR
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD005982. PubMed ID: 32557627
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of thromboprophylaxis with low molecular weight heparin in critically ill patients with COVID-19. An observational prospective, multicenter study.
Ferrandis R; Escontrela B; Ferrando C; Hernández M; Herrera J; Hidalgo F; Librero J; Llau JV; Martínez A; Pajares A; Tapia B; Arruti E; Bassas E; Blasi A; Calvo A;
Rev Esp Anestesiol Reanim (Engl Ed); 2023 Mar; 70(3):129-139. PubMed ID: 36842685
[TBL] [Abstract][Full Text] [Related]
15. The Effect of Heparin Full-Dose Anticoagulation on Survival of Hospitalized, Non-critically Ill COVID-19 Patients: A Meta-analysis of High Quality Studies.
Pilia E; Belletti A; Fresilli S; Lee TC; Zangrillo A; Finco G; Landoni G;
Lung; 2023 Apr; 201(2):135-147. PubMed ID: 36738324
[TBL] [Abstract][Full Text] [Related]
16. Non-severe COVID-19 is associated with endothelial damage and hypercoagulability despite pharmacological thromboprophylaxis.
Kelliher S; Weiss L; Cullivan S; O'Rourke E; Murphy CA; Toolan S; Lennon Á; Szklanna PB; Comer SP; Macleod H; Le Chevillier A; Gaine S; O'Reilly KMA; McCullagh B; Stack J; Maguire PB; Ní Áinle F; Kevane B
J Thromb Haemost; 2022 Apr; 20(4):1008-1014. PubMed ID: 35102689
[TBL] [Abstract][Full Text] [Related]
17. The effect of low-dose and high-dose low-molecular-weight-heparin and aspirin thromboprophylaxis on clinical outcome and mortality in critical ill patients with COVID-19: A retrospective cohort study.
Eman A; Balaban O; Süner KÖ; Cırdı Y; Şahin F; Demir G; Pekşen Ö; Musmul A; Erdem AF
Saudi Med J; 2022 Jul; 43(7):715-722. PubMed ID: 35830988
[TBL] [Abstract][Full Text] [Related]
18. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Bates SM; Greer IA; Pabinger I; Sofaer S; Hirsh J
Chest; 2008 Jun; 133(6 Suppl):844S-886S. PubMed ID: 18574280
[TBL] [Abstract][Full Text] [Related]
19. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Di Nisio M; Porreca E; Otten HM; Rutjes AW
Cochrane Database Syst Rev; 2014 Aug; (8):CD008500. PubMed ID: 25171736
[TBL] [Abstract][Full Text] [Related]
20. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery.
Felder S; Rasmussen MS; King R; Sklow B; Kwaan M; Madoff R; Jensen C
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD004318. PubMed ID: 30916777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
